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Abstract
Background: DYT1 dystonia is an autosomal dominant neurological condition caused by a mutation that removes
a single glutamic acid residue (ΔE) from the torsinA (torA) AAA+ protein. TorA appears to possess a nuclear
envelope (NE) localized activity that requires Lamina-Associated-Polypeptide 1 (LAP1), which is an inner nuclear
membrane localized torA-binding partner. Although hypoactive, the DYT1 dystonia torA-ΔE isoform often
concentrates in the NE, suggesting that torA-ΔE also interacts with an NE-localized binding partner.
Results: We confirm that NE-localized torA-ΔE does not co-immunoprecipitate with LAP1, and find that torA-ΔE
continues to concentrate in the NE of cells that lack LAP1. Instead, we find that variability in torA-ΔE localization
correlates with the presence of the SUN-domain and Nesprin proteins that assemble into the LINC complex. We
also find that siRNA depletion of SUN1, but not other LINC complex components, removes torA-ΔE from the NE. In
contrast, the LAP1-dependent NE-accumulation of an ATP-locked torA mutant is unaffected by loss of LINC
complex proteins. This SUN1 dependent torA-ΔE localization requires the torA membrane association domain, as
well as a putative substrate-interaction residue, Y147, neither of which are required for torA interaction with LAP1.
We also find that mutation of these motifs, or depletion of SUN1, decreases the amount of torA-WT that
colocalizes with NE markers, indicating that each also underlies a normal NE-localized torA binding interaction.
Conclusions: These data suggest that the disease causing ΔE mutation promotes an association between torA and
SUN1 that is distinct to the interaction between LAP1 and ATP-bound torA. This evidence for two NE-localized binding
partners suggests that torA may act on multiple substrates and/or possesses regulatory co-factor partners. In addition,
finding that the DYT1 mutation causes abnormal association with SUN1 implicates LINC complex dysfunction in DYT1
dystonia pathogenesis, and suggests a gain-of-function activity contributes to this dominantly inherited disease.
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Background
DYT1 dystonia is a neurological disease characterized by
prolonged, involuntary movements that develop in child-
hood or early adolescence, and occur in the absence of
CNS pathology [1,2]. The disease is caused by an in-
frame, loss-of-function mutation that removes a glutamic
acid residue (ΔE) from torA [3,4]. TorA is a member of
the AAA+ ATPase family (ATPases Associated with a
variety of cellular Activities) that typically couple the
energy released by ATP hydrolysis to conformational
changes in binding partners. The structural changes
induced by AAA+ proteins vary. However, in most cases,
an oligomeric ring arrangement of AAA+ enzyme subu-
nits pulls the binding-partner substrate into the central
pore and, by doing so, ‘stretches’ or removes secondary
structure from the substrate. This action often destabi-
lizes an otherwise energetically favorable binding interac-
tion, such as the presence of substrate in a protein
complex, aggregate, or association with a lipid bilayer.
There are many hundreds of AAA+ enzymes and sub-
strates, and AAA+ enzymes are used in processes as
diverse as DNA replication, membrane fusion, protein
degradation and cytoskeletal movement [5-7].
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Multiple studies and research groups have found that
torA is an endoplasmic reticulum (ER) resident protein
[8-10]. However, despite localization throughout the ER-
system, torA loss specifically affects the NE subdomain
and this suggests that torA AAA+ activity is targeted to a
NE localized protein [4,11]. It is well established that torA
interacts with the inner nuclear membrane protein,
lamina-associated-polypeptide-1 (LAP1; TOR1AIP1)
[12-15]. The importance of LAP1 is further underscored
by the recent finding that LAP1 loss causes similar NE
abnormalities to those seen in torA null cells [14]. In addi-
tion, the interaction between torA and LAP1 is stabilized
by AAA+ domain mutations that typically inhibit ATP
hydrolysis, such as the WalkerB box E171Q mutation in
human torA [12,13,15]. Since the majority of AAA+ pro-
teins interact with substrate in their ATP bound form, this
stabilization suggests that LAP1 is a torA substrate. To
date, however, the cellular functions of LAP1 remain
unknown, no other luminal binding partners are identified,
and LAP1 levels and subcellular localization appear unaf-
fected by torA loss [4] - a surprising state of affairs for the
predicted substrate of a physiologically important AAA+
protein. Other torA binding partners are also described,
including the Nesprin proteins that are components of the
LINC complex that couples the nuclear interior to cytos-
keletal networks [16]. However, the relationship between
these reported interacting partners, and the biochemical
[12,13,15], genetic [14] and cell biologically [12,13] verified
association between torA and LAP1 remains unclear.
Genetic analysis has demonstrated that the disease-
associated torA-ΔE protein is expressed in DYT1 dystonia,
but is hypoactive or inactive [4,10]. Consistent with these
findings, recent studies demonstrated that ΔE appears to
inhibit torA interaction with LAP1 and the homologous
LULL1 membrane protein [13,15]. However, torA-ΔE can
also concentrate in the NE [10,17], which suggests that ΔE
stabilizes, rather than inhibits, interaction with an NE bind-
ing partner. The possibility that torA-ΔE displays enhanced
NE-localized binding also argues against DYT1 dystonia
being caused by a pure loss-of-function mutation. Further-
more, a gain-of-function activity is also consistent with the
dominant nature of disease inheritance and that the torA-
ΔE generating mutation is the sole causative mutation.
Here we further examined torA-ΔE behavior in order to
determine whether dysfunction of the mutant disease pro-
tein might contribute to DYT1 dystonia pathogenesis. We
describe an association between torA-ΔE and the SUN1
inner nuclear membrane protein, and present data suggest-
ing that SUN1 is also a normal torA binding partner. This
abnormal ability of torA-ΔE provides more evidence for a
gain-of-function action in DYT1 dystonia, and implicates
the neurodevelopmentally important LINC complex dys-
function in disease pathogenesis.
Results
The majority of NE membrane proteins are localized and
immobilized in this ER subdomain by binding to the
nuclear lamina [18,19]. Although torA is a luminal protein,
torA-E171Q and torA-ΔE concentrate in the NE of several
cell lines, and each diffuses more slowly than ER-localized
torA [12], which suggests that both isoforms interact with
a lamina-associated NE membrane protein, such as LAP1.
We examined the LAP1-binding of human torA-ΔE and
torA-E171Q using mouse NIH-3T3 cells where both iso-
forms similarly localize in the NE (Figure 1A), whereas
this is previously assessed using cell lines where torA-ΔE
is predominantly ER-localized [15,20]. However, we also
find that LAP1 specifically co-immunoprecipitates with
(GFP)torA-E171Q, but not (GFP)torA-ΔE (Figure 1B, top
row), despite similar expression and capture of both GFP-
tagged torsinA isoforms (Figure 1B, bottom row). We also
compared (GFP)torA-E171Q and (GFP)torA-ΔE binding
to the ER-localized torA binding partner, LULL1. Again,
we find no detectable co-immunoprecipitation of LULL1
with (GFP)torA-ΔE, although LULL1 is co-captured by
(GFP)torA-E171Q immunoprecipitation (Figure 1B, mid-
dle row). Thus, it appears that the E171Q and ΔE muta-
tions differentially affect binding to the two verified torA
binding partners, even in cell systems where both muta-
tions cause torA to accumulate in the NE.
Co-immunoprecipitation of LAP1 with torA requires
that binding is maintained after detergent solubilization
removes both proteins from the ER membrane. It is there-
fore possible that ΔE inhibits this assessment of torA bind-
ing to LAP1, while interaction in vivo continues to
underlie torA-ΔE localization in the NE, and this could be
exacerbated because we are examining human torA in a
mouse cell line. Consequently, we next examined whether
LAP1 is important for the in vivo localization of torA-ΔE.
To semi-quantitatively assess protein localization in vivo,
we measured the relative amount of NE and ER-localized
protein in individual cells. This method finds ratios of NE/
ER localized fluorescent signal above one for the inner
nuclear membrane proteins of LAP1, LAP2 and emerin
(the mean ratio ± standard error (s.e.m.) of NE/ER loca-
lized LAP1 fluorescence is 2.86 ± 0.05 (n = 25), LAP2 is
1.59 ± 0.05 (n = 10), and emerin is 1.63 ± 0.08 (n = 23)).
In contrast, ER-resident proteins that do not accumulate
in the NE display relative NE/ER fluorescence ratios below
one (mean ± s.e.m. ratio of NE/ER calreticulin fluores-
cence is 0.94 ± 0.04, n = 12, and protein disulphide iso-
merase (PDI) is 0.79 ± 0.19, n = 25).
We subsequently co-transfected NIH-3T3 cells with
(GFP)torA-WT, (GFP)torA-ΔE, or (GFP)torA-E171Q,
together with scrambled control or LAP1 siRNA
duplexes. In agreement with previous reports where
LAP1 was required for the NE accumulation of (GFP)
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torA-E171Q [14,21], the semi-quantitative analysis
detected that LAP1 depletion significantly reduces the
mean ratio of NE/ER localized (GFP)torA-E171Q fluor-
escence (Figure 1C). However, in contrast, LAP1 knock-
down did not affect the ratio of NE/ER (GFP)torA-ΔE
fluorescent signal (Figure 1C). Qualitative analysis simi-
larly highlights that (GFP)torA-ΔE is strongly concen-
trated in the NE of LAP1 depleted cells (Figure 1D;
central panels), while the absence of LAP1 inhibits the
NE-accumulation of (GFP)torA-E171Q, which is instead
predominantly ER-localized (Figure 1D; right column).
Although torA-WT is previously shown to biochemically
associate with LAP1 [13,15], and LAP1 overexpression
increases the amount of NE-localized (GFP)torA-WT
[12], we failed to detect LAP1-induced change in (GFP)
torA-WT localization. However, this may be due to the
insensitivity of our measurements, rather than absence
of in vivo interaction between torA-WT and LAP1.
Figure 1 TorA-ΔE does not interact with the NE-localized torA-E171Q binding partner, LAP1. (A) (GFP)torA-ΔE and (GFP)torA-E171Q both
concentrate in the NE of NIH-3T3 cells. The * symbol highlights a cell with ER-localized (GFP)torA-ΔE. Scale bars show 10 μm. (B) LAP1 and
LULL1 co-immunoprecipitate with (GFP)torA-E171Q and not (GFP)torA-ΔE. Left panels show levels of LAP1, LULL1 and (GFP)torA in 5% of lysate
input collected from control, (GFP)torA-E171Q or (GFP)torA-ΔE stably expressing NIH-3T3 cells. Anti-LAP1 (top row) detects the alternatively
spliced LAP1 isoforms [14,43] and anti-LULL1 (middle row) detects 75 kD LULL1. Right panels show levels of LAP1, LULL1, or GFP that
immunoprecipitate with anti-GFP in buffer containing 2 mM ATP and 0.5 mM ADP. Note: mild elution conditions were used to prevent release
of captured anti-GFP IgG molecules. (C) LAP1 depletion specifically affects (GFP)torA-E171Q localization. Columns show the mean and s.e.m. for
ratios of NE/ER localized GFP fluorescence from n > 25 NIH-3T3 cells co-transfected with scrambled or LAP1 siRNA duplexes and (GFP)torA
isoforms. *** symbol indicates that LAP1 depletion significantly reduces the (GFP)torA-E171Q NE/ER fluorescence ratio (p < 0.001; Two-Way
ANOVA with Bonferroni post-hoc analysis). (D) (GFP)torA-ΔE remains NE-localized in LAP1 depleted cells, while (GFP)torA-E171Q redistributes into
the ER. Images show anti-GFP labeling of NIH-3T3 cells co-transfected with (GFP)torA isoforms and control (upper row) or LAP1 siRNA duplexes
(lower row). Scale bars show 10 μm.
Jungwirth et al. BMC Cell Biology 2011, 12:24
http://www.biomedcentral.com/1471-2121/12/24
Page 3 of 12
LINC complex components are required for torA-ΔE
localization in the NE
This lack of interaction between torA-ΔE and LAP1
reveals that a distinct mechanism underlies the NE-accu-
mulation of the disease-associated torA isoform. Further-
more, although (GFP)torA-ΔE concentrates in the NE of
the majority of NIH-3T3 and BHK21 cells, we consis-
tently observe a minority of cells where (GFP)torA-ΔE is
diffusely distributed through the ER (Figure 1A, where
the * symbol highlights a cell with ER-localized (GFP)
torA-ΔE), and this variability does not correlate with
levels of LAP1 (not shown). We hypothesized that this
inconsistency in torA-ΔE localization might reflect the
variable presence of a NE-localized torA-ΔE binding
partner and we proceeded to examine the subcellular
localization of several NE membrane proteins. We
focused on the LINC complex proteins that couple the
nucleus with cytoskeletal networks, as these have pre-
viously been associated with torA [16,20]. The LINC
complex is formed in the NE lumen between inner
nuclear membrane SUN-domain proteins and outer
nuclear membrane Nesprins, and we find that NIH-3T3
cells express both of the functionally homologous SUN1
and SUN2 proteins [22,23]. We also detect NE-localized
Nesprin2 in NIH-3T3 cells, although Nesprin1 is absent
[24] and anti-Nesprin3 signal appears Golgi-localized
(Additional File 1, Figure S1), thus indicating that
Nesprin2 is the predominant Nesprin protein of NIH-
3T3 cells.
While the majority of NIH-3T3 cells possess NE-loca-
lized anti-SUN1, anti-SUN2 and anti-Nesprin2 immu-
noreactivity, we also observe some interphase cells with
minimal amounts of NE-localized fluorescent signal, or
punctate anti-LINC component immunoreactivity out-
side of the NE (Figure 2A shows SUN1 localization). In
contrast, the inner nuclear membrane proteins of emerin,
LAP1 and LAP2 are consistently NE-localized in inter-
phase cells (not shown), suggesting that this variability is
LINC complex specific. We consequently examined
whether (GFP)torA-ΔE localization correlates with the
variability in LINC complex protein localization and
found that cells with NE-localized anti-SUN1, anti-SUN2
or anti-Nesprin2 labeling also display NE-localized (GFP)
torA-ΔE (Figure 2B-D). In contrast, (GFP)torA-ΔE is dif-
fusely distributed through the ER system in cells that lack
NE-localized LINC complex components, or when these
were present at low levels (Figure 2B-D, cells highlighted
by * symbols). Furthermore, we often also observed that
(GFP)torA-ΔE co-localized with SUN1-immunoreactive
puncta outside the NE (Figure 2B; white arrow head). We
subsequently confirmed this qualitative association
between (GFP)torA-ΔE and LINC complex localization
by examining the ratio of NE/ER localized anti-SUN1,
anti-SUN2 and anti-Nesprin2 fluorescence in cells with
Figure 2 TorA-ΔE co-localizes with LINC complex components.
A) SUN1 localization in the NE varies between individual NIH-3T3
cells. Panels show anti-SUN1 (red), DAPI labeling of DNA, anti-PDI
labeling of the ER (green) in sub-confluent, unsynchronized NIH-3T3
cells. Scale bars show 10 μm. (B - D) Positive correlation between
the localization of LINC complex components and transfected (GFP)
torA-ΔE. Left panels (red) show (B) anti-SUN1, (C) anti-SUN2, and (D)
anti-Nesprin2 labeling of NIH-3T3 cells. Middle panels (green) show
the subcellular localization of transfected (GFP)torA-ΔE. * symbols
highlight that cells with ER-localized (GFP)torA-ΔE also lack NE-
localized LINC proteins. White arrowheads highlight that transfected
(GFP)torA-ΔE also colocalizes with SUN1 outside the NE. (E) Ratios of
NE/ER localized anti-SUN1, SUN2 and Nesprin2 fluorescence are
higher in cells with NE-localized (GFP)torA-ΔE. Columns show the
mean and s.e.m. of the relative NE/ER localized anti-SUN1, SUN2,
Nesprin2, LAP1, emerin and LAP2 fluorescence from n > 15 cells.
Black columns show the ratios of NE/ER fluorescence from cells with
predominantly NE-localized (GFP)torA-ΔE, while grey columns show
ratios from cells with ER-localized (GFP)torA-ΔE. ***, ** indicate that
the mean ratio of NE/ER fluorescence is significantly (p < 0.001,
0.01) different between cells with NE- or ER-localized (GFP)torA-ΔE
(Two-Way ANOVA with Bonferroni post-hoc analysis).
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either NE- or ER-localized (GFP)torA-ΔE. This analysis
found that the ratios of NE/ER localized LINC complex
components were significantly higher for cells with NE-
localized (GFP)torA-ΔE (Figure 2E, black columns), com-
pared with cells where (GFP)torA-ΔE is predominantly
present in the main ER (Figure 2E, grey columns). In
contrast, we found no correlation between torA-ΔE loca-
lization and the relative NE/ER levels of LAP1, emerin or
LAP2 (Figure 2E).
We next examined whether any LINC complex com-
ponents are required for torA-ΔE to localize in the
NE. We co-transfected NIH-3T3 cells with (GFP)torA
isoforms alongside scrambled control siRNA duplexes,
or SUN1, SUN2, or Nesprin2 siRNA duplexes that
were verified to reduce expression of each LINC com-
plex component (Additional File 1, Figure S1B - D).
This revealed that SUN1 is required for (GFP)torA-ΔE
to concentrate in NE, and we find ER-localized (GFP)
torA-ΔE, or a punctate distribution of (GFP)torA-ΔE,
in cells lacking SUN1 (Figure 3A middle row). As
expected, this change in subcellular localization is
reflected by a significant decrease in relative NE/ER
(GFP)torA-ΔE fluorescence between control and SUN1
depleted cells (Figure 3B). In contrast, (GFP)torA-
E171Q continues to concentrate in the NE of SUN1
siRNA treated cells (Figure 3A, bottom row) and
SUN1 siRNA does not appear to alter the relative NE/
ER localization of (GFP)torA-E171Q (Figure 3B). This
suggests that SUN1 loss specifically affects torA-ΔE
without perturbing all NE-localized interactions. We
do not observe gross differences in the localization of
any torA isoform after SUN2 or Nesprin2 depletion
(not shown). We also determined that the relative NE/
ER fluorescence of both (GFP)torA-ΔE and (GFP)torA-
E171Q remains high in SUN2 siRNA transfected cells
(Figure 3C). Surprisingly, this semi-quantitative analy-
sis identified that Nesprin2 depletion increases the
ratio of NE/ER localized (GFP)torA-ΔE (Figure 3D).
Thus, although Nesprins are identified as torA-binding
proteins [16], it appears that removing Nesprin2 may
increase the number of NE-localized torA-ΔE binding
sites.
Figure 3 TorA-ΔE localization in the NE requires SUN1. (A) SUN1 depletion selectively inhibits the NE-localization of (GFP)torA-ΔE. Images
show anti-GFP labeling of NIH-3T3 cells co-transfected with (GFP)torA isoforms and control (left panels) or SUN1 siRNA duplexes (right panels).
Scale bar shows 10 μm. (B - D) Only SUN1 siRNA reduces the ratio of NE/ER localized (GFP)torA-ΔE fluorescence. Columns show the mean and
s.e.m. of the relative NE/ER GFP fluorescence from n > 25 NIH-3T3 cells transfected with (GFP)torA isoforms alongside (B) SUN1, (C) SUN2, or (D)
Nesprin2 siRNA duplexes, or a sequence matched scrambled control siRNA duplex. The ** and *** symbols indicate a significant (p < 0.01,
< 0.001, respectively) difference between control and siRNA treated cells. (Two-Way ANOVA with Bonferroni post-hoc analysis).
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TorA-WT and torA-ΔE localization in the NE requires
motifs that are not involved in torA-E171Q interaction
with LAP1
These observations suggest that an association exists
between torA-ΔE and the SUN1 LINC complex compo-
nent, and therefore that SUN1, rather than LAP1, may be
an NE partner of torA-ΔE. We subsequently examined
whether these two putative torA binding interactions
require distinct torA domains or residues. We first inves-
tigated the importance of the torA membrane association
domain that immediately follows the cleaved ER targeting
sequence [20,25] (Figure 4A). We transfected NIH-3T3
cells with either full-length (GFP)torA isoforms, or torA
isoforms that lacked residues 22 to 40 (Δ22-40) that
includes the membrane-association domain. We found
that (GFP)torA-E171Q lacking residues 22-40 continues
to accumulate in the NE (Figure 4B middle row), indicat-
ing that this domain is not required for LAP1 binding, as
is consistent with previous study of the torA - LULL1
interaction [20]. In contrast, Δ22-40 inhibits the NE-con-
centration of (GFP)torA-ΔE, and we fail to observe any
cells with NE-localized (GFP)torA-ΔE when residues
22-40 are removed (Figure 4B). We also observed
that Δ22-40 appeared to decrease the amount of NE-
localized torA-WT (Figure 4B top row). We therefore
semi-quantitatively examined (GFP)torA-WT localiza-
tion, which revealed that introduction of Δ22-40 caused
a significant (p < 0.001, Students Two-Tailed T-Test)
decrease in the relative amount of NE/ER localized (GFP)
torA-WT fluorescence from a mean ± s.e.m. of 1.15 ±
0.03 to 0.98 ± 0.03 (n = 25). Thus, the membrane associa-
tion domain of torA is both essential for the SUN1-
dependent NE accumulation of torA-ΔE, and appears to
play a role in a torA-WT localization, despite not affect-
ing torA interaction with LAP1 or LULL1.
We also explored whether other torA motifs are impor-
tant for torA localization in the NE. AAA+ enzymes typi-
cally alter substrate conformation using aromatic amino-
acid residues that line the pore of the assembled AAA+
ring structure. Work with model AAA+ proteins has sug-
gested that these residues interact with substrate and
undergo ‘lever-like’ movements to pull substrates into
the central pore [26-28]. We identified a torA tyrosine
residue (Y147 in human torA) that lies in the approxi-
mate position of other AAA+ substrate-binding tyrosine
residues. Furthermore, this residue is conserved between
all vertebrate and invertebrate torA homologs (torsin
family proteins [21]), suggesting a functional importance
in torsin enzyme activity. With the hypothesis that this
residue may be specifically important for torA binding
with substrate, we compared how mutation (Y147A)
affects (GFP)torA-ΔE localization in the NE compared
with the LAP1-dependent NE-localization of (GFP)torA-
E171Q. As with residues 22-40, we observed that the
Y147A mutation specifically inhibits the NE-localization
of (GFP)torA-ΔE, while (GFP)torA-E171Q continues to
accumulate in the NE (Figure 4B, right column). We
again also observed an apparent loss of NE-localized
(GFP)torA-WT fluorescent signal and therefore semi-
quantitatively examined how Y147A affects (GFP)torA-
WT localization. This revealed that the Y147A mutation
significantly reduces (p < 0.05, Students Two-Tailed
T-Test) the ratio of NE/ER (GFP)torA-WT fluorescence
from a mean ± s.e.m. of 0.98 ± 0.02, to 0.90 ± 0.02 (n =
45). Thus, the Y147 residue is required for both the NE-
Figure 4 A putative membrane association domain and pore-
lining residue are required for torA-ΔE localization in the NE.
(A) Schematic of torA structure showing the location of amino-
terminal ER targeting sequence, putative membrane association
domain, together with the Y147, E171 and E302/3 (mutated by ΔE)
residues. (B) Images show anti-GFP labeling of BHK21 cells
expressing (left panels) “control” (GFP)torA-WT, (GFP)torA-ΔE or (GFP)
torA-E171Q proteins, or (central column) these torA isoforms lacking
residues 22 - 40 ("Δ22-40”), or (right column) torA isoforms
containing the Y147A mutation ("+ Y147A”). Scale bars show 10 μm.
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concentration of torA-ΔE, as well as for torA-WT to
localize in the NE.
SUN1 depletion removes torA-WT from the NE
The importance of 22-40 and Y147 for WT and torA-ΔE
localization in the NE suggests that these torA isoforms
form a similar, LAP1-independent, binding interaction.
Consistent with this hypothesis, we often observed that
SUN1 depletion reduced the small amount of NE-loca-
lized (GFP)torA-WT fluorescence present in most cells
[10,29] (Figure 5). Our initial analysis found that SUN1
siRNA did not significantly decrease the ratio of NE/ER
localized (GFP)torA-WT fluorescence. However, since a
proportion of control treated cells also lack NE-localized
SUN1 (Figure 2A shows variability in SUN1 levels), we
hypothesized that our approach may have yielded a false-
negative result. Consequently, we reassessed the ratio of
NE/ER localized (GFP)torA-WT fluorescence in indivi-
dual control siRNA transfected cells that we verified pos-
sessed SUN1, and compared this with cells that were
SUN1 siRNA treated and verified to lack SUN1. This
analysis found that the control ratio of NE/ER (GFP)
torA-WT fluorescence in SUN1-containing cells (mean ±
s.e.m. of 1.03 ± 0.02 (n = 34)) is significantly reduced (p <
0.0001, Students Two Tailed T-Test) to 0.89 ± 0.02 (n =
41) when SUN1 siRNA transfection depletes cellular
SUN1. Thus, it appears that some torA-WT is normally
SUN1-associated in vivo, which suggests SUN1 is a nor-
mal torA partner, as well as the protein responsible for
the abnormal NE accumulation of disease-associated
torA-ΔE.
Discussion
LAP1 has been consistently identified as a NE-localized
binding partner of torA [12,14,15,20], and it appears that
LAP1 is required for NE-localized torA activity [14]. How-
ever, we find that the NE localization of both torA-WT
and torA-ΔE require torA-motifs that are unimportant for
the LAP1 interaction. Furthermore, we show that SUN1
depletion removes torA-WT and torA-ΔE from the NE,
while LAP1 is not required for torA-ΔE to concentrate in
the NE. Therefore, although LAP1 is the confirmed bind-
ing partner for ATP-bound torA, LAP1 is neither the sole
NE-localized torA interacting protein nor the partner of
disease-associated torA-ΔE.
The multiple differences between torA-E171Q and
torA-ΔE reveal that distinct mechanisms underlie their
superficially similar ability to concentrate in the NE lumen
[13,15]. While it appears that the E171Q mutation traps
torA in an ATP-bound state, the mechanism by which ΔE
affects torA remains unclear. A previous genetic analysis
found that torA-ΔE cannot compensate for torA loss,
therefore revealing that this isoform is hypoactive or inac-
tive [4]. Biochemical analysis has also demonstrated that
torA-ΔE may fail to bind ATP, or perhaps fail to undergo
a structural rearrangement on ATP-binding [15], either of
which may explain why torA-ΔE cannot form the ATP-
dependent interaction with LAP1 or LULL1 [13,15].
Despite these inhibitory effects, our data now highlight
that ΔE does not generate a ‘dead’ torA isoform that is
incapable of all binding interactions. Instead, the abnormal
association between torA-ΔE and SUN1 suggests that ΔE
‘traps’ torA in a specific conformation that is distinct
to the ATP-bound state. This finding also provides further
evidence that the DYT1 ΔE mutation has a gain-of-
function activity, in addition to producing the previously
characterized impairment of torA function.
Our data indicate that torA associates with the SUN1
LINC complex component, and that the DYT1 mutation
abnormally promotes or stabilizes this interaction. SUN1
is an inner nuclear membrane component of the LINC
Figure 5 SUN1 depletion also reduces NE-localized torA-WT.
The (GFP)torA-WT normally present in the NE of NIH-3T3 cells is
reduced by SUN1 siRNA treatment. Images show anti-GFP labeling
of NIH-3T3 cells expressing (GFP)torA-WT (green) and transfected
with control (left) or SUN1 siRNA duplexes (right). Anti-LaminA/C
labeling (red) highlights the position of the NE and lower panels
show the merge (yellow) of (GFP)torA-WT and NE-marker signals,
with less yellow signal present in the cell lacking SUN1. Scale bars
show 10 μm.
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complex that couples the nuclear interior to cytoskeletal
networks. SUN1 has a nucleoplasmic domain that med-
iates interaction with lamins, an extended membrane
spanning hydrophobic region, and an approximately
50 kD luminal domain that appears to mediate both
SUN-protein multimerization and interaction with
KASH-domains of outer nuclear membrane Nesprin
proteins [30-33]. There is loss-of-function evidence for
functional redundancy between SUN1 and the similarly
widely expressed and homologous SUN2 [22,23]. It is
therefore surprising to find that SUN1 is specifically
required for torA localization in the NE. We cannot
rule out that SUN1 is selectively required because NIH-
3T3 cells predominantly rely on SUN1, or that SUN1
siRNA more efficiently depletes SUN1 from the NE.
However, there are reported differences in SUN1 and
SUN2 characteristics [20,22,24,34], and our finding that
SUN1 is selectively important for torA localization pro-
vides further evidence that these proteins have distinct,
as well as overlapping cellular roles.
We do not resolve whether torA interacts directly or
indirectly with SUN1. However, there is evidence against
the possibility that SUN1 loss causes general NE disrup-
tion that removes torA by a highly indirect mechanism.
Several previous studies have shown that NE structure
and LINC complex function are largely normal in the
absence of SUN1, and that combined SUN1 and SUN2
loss is required to perturb NE morphology [23,30,35,36].
Consistent with these findings, we observe that the
NE-localization of LAP1-associated torA-E171Q is undis-
turbed by SUN1 loss, and that other inner nuclear mem-
brane proteins are normally localized in cells lacking
SUN1 (not shown). Furthermore, we also find that torA-
ΔE colocalizes with SUN1 in puncta that lie outside of
the NE. Thus, while it is possible that torA indirectly
associates with SUN1, any such indirect interaction
would be mediated by a protein or proteins that are also
tightly coupled to SUN1. Unfortunately, we were unable
to biochemically verify that a direct or indirect interac-
tion exists between torA and SUN1. Like many inner
nuclear membrane proteins, SUN1 solubilization requires
that ionic detergents disrupt binding to the nuclear
lamina and chromatin [31]. This treatment necessarily
also impairs luminal interactions and a failure to detect
biochemical association does not preclude that SUN1
and torA interact in vivo. Furthermore, despite our nega-
tive findings with anti-GFP immunoprecipitation of
(GFP)torA isoforms, one previous report described that
nesprin KASH-domains co-immunoprecipitate with anti-
torA antibodies [16], which provides general support
for an interaction between torA and a LINC complex
component. However, our finding that Nesprin2 deple-
tion increases, rather than decreases, the amount of NE-
localized torA-ΔE, indicates that this previous result
reflects an indirect, rather than direct, interaction
between torA and nesprins. It is unclear why Nesprin2
loss increases torA-ΔE localization in the NE. However,
an increased number of torA-ΔE binding sites, perhaps
caused by compensatory upregulation of other LINC
components, could account for both our observations
and the previous association between torA and the
nesprin KASH-domain.
Our findings support a model where torA interacts
with at least two different NE proteins [16]. The exis-
tence of additional NE-localized partners suggests that
torA either operates on multiple substrates and/or that
some identified torA interacting partners have a regula-
tory function and are not subject to torA AAA+ activity.
Finding that the SUN1-dependent localization requires a
putative substrate interaction residue [26,28], Y147, sug-
gests that SUN1 or the LINC complex is a substrate
affected by torA AAA+ activity. Surprisingly, this also
suggests that Y147A destabilizes an interaction that is
distinct to the ATP-bound torA state that associates with
LAP1 and LULL1. This insensitivity of LAP1 and LULL1
binding raises the possibility that these proteins are not
torA substrates. Furthermore, these data also suggest that
torA could operate using an atypical biochemical AAA+
mechanism; a hypothesis that is supported by the pre-
sence of a non-canonical nucleotide binding motif in the
torA AAA+ domain that appears to convey preferential
binding to ADP, rather than ATP [37].
The possibility that torA activity modifies the LINC
complex is also supported by two previous reports. In one
study, torA loss appeared to remove the Nesprin3 LINC
complex component from the NE, suggesting that torA
normally maintains intact LINC complexes [16]. In con-
trast, a separate study made the reverse observation, and
found that overexpression of the LULL1 torA-binding
partner appeared to induce a NE-localized torA activity
that removed SUN2 and Nesprin2 [20]. This LULL1-
activated torA was strongly concentrated in the NE of
cells that lacked SUN2 and Nesprin2, which supports our
finding that SUN1 is important for the NE retention of
torA. Furthermore, since AAA+ activity often disassem-
bles otherwise stable protein complexes [6,38], this data is
also consistent with torA dissociating SUN1 binding inter-
actions to release SUN1-associated proteins from the NE
lumen. The relationship between the LULL1-overexpres-
sion paradigm and physiological torA function is unclear,
and there are some AAA+ proteins that promote protein
complex formation or remodeling, rather than disassembly
[39]. Therefore, a difference between the actions of physio-
logical levels of torA activity, versus overactive torA
enzymes, could explain the discrepancy between these two
studies.
While our study emphases a relationship between
torA and the LINC complex, it is also clear that LAP1
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has a central role in torA function and, notably, LAP1
and torA gene knock-out result in the same NE mem-
brane abnormalities [14]. Although this association does
not resolve whether LAP1 activity is upstream (an
essential torA regulator/co-factor) or downstream (a
substrate) of torA activity, it is clear that LAP1 is the
partner of the ATP-bound form of torA that is typically
the substrate-associated state of a AAA+ protein [13,15].
There are examples of promiscuous AAA+ enzymes that
operate on several distinct substrate proteins, and it is
possible that torA is a multi-functional AAA+ protein
that operates on both LAP1 and the LINC complex.
Furthermore, since adapter proteins often regulate the
substrate selection of multifunctional AAA+ proteins
[40], the importance of Y147, residues 22-40, and the
effect of ΔE, could be explained if these motifs affect
torA interaction with an adapter that promotes the
LINC complex association over LAP1 binding.
Our study is performed using cells that also express
torA. It is therefore possible that these endogenous
torA-WT subunits play a role in the association between
(GFP)torA-ΔE and SUN1. Nevertheless, mixed torA-ΔE
and torA-WT expression also occurs in DYT1 dystonia,
and it is demonstrated that torA abnormally concen-
trates in the NE of DYT1 dystonia cells, as well as neu-
rons ectopically expressing torA-ΔE [10,29]. Thus, our
findings suggest that the LINC complex of DYT1 dysto-
nia neurons is abnormally associated with torA-ΔE.
There are several mechanisms by which an abnormal
association between torA-ΔE and SUN1 could negatively
impact cell function. Firstly, torA-ΔE occupation of
binding sites could prevent functional torA enzymes
from accessing the LINC complex, and therefore inhibit
torA activity in the event that this normally modifies the
LINC complex. Secondly, there is evidence that torA-
WT and torA-ΔE co-oligomerize, and that the abnormal
SUN1-association of torA-ΔE is conferred to co-
expressed torA-WT [10]. This could result in torA-WT
sequestration away from other molecular targets of torA
AAA+ activity. A third possibility is that abnormal asso-
ciation with torA-ΔE directly impacts LINC complex
assembly or function, independent of torA-WT activity.
These mechanisms are not mutually exclusive, and it is
possible that a combination of such loss-of-function
and/or gain-of-function torA-ΔE actions underlie why
DYT1 dystonia is dominant and the torA-ΔE generating
mutation is the only identified cause of this disease.
Our study did not identify grossly abnormal LINC
complex component localization in cells transfected to
express (GFP)torA-ΔE. However, our assessment did
not examine whether physiological torA-ΔE expression
impacts LINC complex components as these are utilized
during particular cellular behaviors, such as nuclear
movement [23,24]. It is unlikely that torA-ΔE expression
completely ablates LINC complex activity, as genetic
deletion of the complex in mice results in severe neuro-
developmental abnormalities [23], compared with unde-
tectable or limited neuropathology in human DYT1
dystonia patients and heterozygous torA-ΔE expressing
mice [41]. However, given the importance of the LINC
complex for nervous system development [23], it is con-
ceivable that torA-ΔE driven abnormalities in LINC
complex mediated events impact neuronal development
to generate the circuit abnormalities that are thought to
underlie the debilitating twisting movements of DYT1
dystonia [42].
Conclusions
We have demonstrated an association between the
DYT1 dystonia protein, torA-ΔE, and the SUN1 compo-
nent of the LINC complex. We also find evidence that
SUN1 is a normal torA partner, which therefore sug-
gests that the ΔE mutation stabilizes a normally transi-
ent torA binding interaction. These findings raise the
possibility that torA-ΔE may impact the LINC complex,
and therefore implicate LINC complex dysfunction in
DYT1 dystonia.
Methods
Cell culturing and transfection
We obtained NIH-3T3 and BHK21 cells from ATCC
and cultured these under recommended conditions.
Transfections were performed for 3 hours with cells pla-
ted onto collagen-coated coverglasses in 24 well plates
using Plus Reagent with either Lipofectamine or Lipo-
fectamine LTX. siRNA transfection of NIH-3T3 cells
was performed using 25 pmol dsRNA and RNAiMAX
reagent. Dual plasmid and RNA transfection of ~ 30%
confluent NIH-3T3 cells was performed using 200 ng
DNA, 25 pmol dsRNA and Lipofectamine 2000. All
transfection reagents were purchased from Invitrogen
and used according to the manufacturers recommenda-
tions except as noted above. We generated (GFP)torA
stably expressing NIH-3T3 lines by placing plasmid
transfected cells under selection with 1 mg/ml G418
(Fisher Scientific) until patches of cells were visible.
Individual colonies were collected by trypsinization,
expanded in the continued presence of G418, and
assayed for torA expression. All other transfections were
performed at least twice and coverslip cultured cells
were fixed with formaldehyde at 24 hours post-transfec-
tion (plasmid transfections) or between 36 and 48 hours
post-transfection (siRNA transfections).
Plasmid generation and siRNA sequences
The methods and production of torA expression con-
structs are previously described [10,12]. We generated
torA cDNA constructs that lacked residues 22-40 by
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first using QuikChange PCR mutagenesis to introduce
Nhe1 sites between residues 21 and 22, and between 40
and 41, of human torA. We then replaced the sequence
between the Nhe1 sites with GFP from pEGFP1 (Clon-
tech). QuikChange was also used to introduce the
Y147A mutation. All torA cDNA sequences were fully
sequenced following PCR based mutagenesis.
siRNA duplexes were custom synthesized by Invitrogen.
Mouse Tor1aip1 (LAP1) siRNA duplex sequence begins at
basepair 956 in NM_144791 and is previously described
[21]. Mouse Unc84a (SUN1) siRNA duplex sequence
begins at basepair 261 in NM_024451: (GCU AUU GAU
UCG CAC AUU A; UAA UGU GCG AAU CAA UAG C)
and is matched with control duplex (GCU UAG UCG
CUA CAU AUU A; UAA UAU GUA GCG ACU AAG C).
Mouse Unc84b (SUN2) begins at basepair 2142 in
NM_194342: (GCA GGA AGG GAC ACU UCU U; AAG
AAG UGU CCC UUC CUG C) and is matched with con-
trol duplex (GCA GGA AAC AGU UCG GCU U; AAG
CCG AAC UGU UUC CUG C). Mouse Syne2 (Nesprin2)
begins at basepair 21173 in NM_001005510 and contains
sequence from the transmembrane and KASH domain
encoding terminal exon of nesprin2: (AUA UAG GUC
AUU UAC GUG C; GCA CGU AAA UGA CCU AUA U)
and is used with control duplex (GCA AAU GUA CCA
AUC GUA UTT; AUA CGA UUG GUA CAU UUG
CTT). Mouse 4831426I19Rik (Nesprin3) siRNA duplex
sequence begins at basepair 2732 of NM_172500, which is
within the terminal exon that contains the KASH domain
sequence: (GCU GUU GCU CCU GCU CUU UTT; AAA
GAG CAG GAG CAA CAG CTT) and this is matched
with control duplex (GCU UCG UGU CCC UCU GUU
UTT; AAA CAG AGG GAC ACG AAG CTT).
Fluorescent imaging, quantification and statistical analysis
Immunofluorescent labeling of coverslip cultured cells is
previously described [21]. Quantification of the relative
amounts of NE and ER localized (GFP)torA fluorescence
was performed on transfected cells co-labeled with antibo-
dies against GFP and the ER marker Protein Disulphide
Isomerase (PDI). We also either colabeled cells, or pro-
cessed duplicate sets of transfected cells, with antibodies
that detect siRNA-targeted proteins to assess the efficiency
of target protein knock-down. All images of target pro-
teins were removed prior to assessment of GFP localiza-
tion to ensure that quantification of (GFP)torA NE/ER
fluorescence ratios was conducted blind to both the
siRNA treatment and torA isoform.
Labeled samples were examined using a Nikon Eclipse
Ti inverted microscope and imaged with Nikon Digital
Sight DS-QiMc camera and NIS-elements BR3.0 soft-
ware. Images of GFP positive cells were captured so that
the focal plane visualized the NE. Exposure times were
100 milliseconds or greater and images with saturated
signal were excluded to avoid analysis of highly expres-
sing cells. A one-pixel wide measuring line was posi-
tioned to bisect the NE and a portion of PDI-labeled ER.
The peak of NE localized pixel intensity was used as mea-
sure of NE fluorescence. We reduced the possibility of
biasing ER fluorescence measurements by consistently
determining GFP signal in a region of PDI-positive peri-
nuclear ER. Thus, ER localized GFP signal was calculated
as the average intensity of pixels between 0.5 μm to 1 μm
distance from the NE. We recorded a ‘Background’ fluor-
escence measurement from an untransfected cell within
the field and subtracted this value from the NE and ER
fluorescence measurements. The intensity of anti-LAP1,
SUN1, SUN2, Nesprin2, LAP2, and emerin NE and ER
immunofluorescent signals were similarly collected, with
the exception that quantification was performed from
cells containing either NE- or ER-localized (GFP)torA-
ΔE, and background corrections were made from a sec-
tion of image that lacked adherent cells. A similar proce-
dure was used to determine the ratio of NE/ER localized
(GFP)torA-WT fluorescence from verified SUN1 positive
or negative cells. In all cases, we used GraphPad prism to
analyze the ratios of NE/ER localized fluorescence col-
lected from individual cells, including calculation of
mean, s.e.m., Two-Way ANOVA, T-Test, and post-hoc
analyses. All graphs show the mean and standard error
(s.e.m.) of these values.
Immunoprecipitations and Western blotting
Confluent dishes of control or (GFP)torA expressing NIH-
3T3 cells were collected, pelleted and solubilized in buffer
containing 50 mM imidazole-HCl (pH 7.5), 5% glycerol,
0.5% digitonin, 4 mM MgCl2, 50 mM NaCl, 1X protease
inhibitor cocktail, 2 mM PMSF and nucleotides as indi-
cated. We removed insoluble material by centrifugation at
20, 000 × g and then incubated lysates for 2.5 hour at 4°C
with anti-GFP conjugated AminoLink resin (Pierce). We
subsequently washed the agarose resin twice with solubili-
zation buffer and eluted captured proteins by 24°C incuba-
tion with non-reducing 2X Laemmli buffer. Elutes and
lysates were analyzed using standard SDS-PAGE and
Western blotting procedures.
Antibodies
Rabbit anti-GFP and anti-LAP1 antibodies are previously
described [21]. We used rabbit polyclonal anti-SUN1
(AbCam), anti-SUN2 (UNC84B) from Sigma and an anti-
SUN2 from AbCam. We also used previously described
procedures [21] to generate rabbit serum containing
polyclonal antibodies against the recombinant luminal
domain of SUN1 [30] that we expressed and purified
from BL21-RIPL E. coli (Stratagene). Anti-Nesprin1
(Abcam), anti-Nesprin2 (Santa Cruz), anti-Nesprin3
(Abcam), anti-emerin (Santa Cruz), anti-LAP2 (Sigma),
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chicken anti-GFP (AbCam), goat anti-laminA/C (Santa
Cruz) and anti-PDI (Assay Designs), are other commer-
cially available antibodies used in this study. Immuno-
fluorescent labeling of cells utilized anti-mouse, chicken
or rabbit secondary antibodies conjugated to DyLight
488, FITC or Rhodamine RedX (Jackson Immunorea-
gents), or AlexaFluor350 conjugated donkey anti-goat
(Invitrogen). Primary antibodies used in Western blotting
were detected using peroxidase conjugated goat anti-rab-
bit secondary antibody (Pierce) or an anti-rabbit light-
chain specific secondary antibody (Jackson Immunolabs).
Additional material
Additional file 1: Figure S1. LINC complex components are depleted
by siRNA transfection of NIH-3T3 cells.
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